Payment overview · 2025
General Payments
$1,371.97
79 reported records · 19 companies
Healthcare provider profile · identity verified
Bernard J Buchanan, M.D., PHD
Allopathic & Osteopathic Physicians|Internal Medicine · OWENSBORO, KY · NPI 1881623395
Verified facts
What the public records show
CMS Open Payments records show Bernard J Buchanan, M.D., PHD received $1,371.97 in general payments during 2025 across 79 reported records.
Amgen Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Prolia, Rybelsus, Xyosted.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xyosted by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 398 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $335.00 | 24.4% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $307.85 | 22.4% | 20 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $158.41 | 11.6% | 11 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$156.37 | 11.4% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $58.32 | 4.2% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $57.31 | 4.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.97 | 3.1% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $37.10 | 2.7% | 2 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $31.71 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.46 | 2.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.10 | 2.0% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $19.28 | 1.4% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $18.78 | 1.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.07 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.58 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.36 | 1.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.00 | 1.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.81 | 1.1% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $14.49 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,329.47 | 78 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $245.23 | 16 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $216.52 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $205.88 | 14 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $158.41 | 11 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $156.37 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $65.21 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.62 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $58.32 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $57.31 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $53.27 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.99 | 3 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $31.71 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.10 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 398 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 410 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 35 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 22 |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
398 | 80 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
410 | 91 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1044 | 242 |
| Gabapentin | Gabapentin | 584 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 563 | 135 |
| Synthroid | Levothyroxine Sodium | 558 | 120 |
| Losartan Potassium | Losartan Potassium | 546 | 137 |
| Doxazosin Mesylate | Doxazosin Mesylate | 532 | 140 |
| Allopurinol | Allopurinol | 495 | 111 |
| Metformin Hcl | Metformin Hcl | 480 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 110 |
| Lisinopril | Lisinopril | 432 | 121 |
| Ozempic | Semaglutide | 410 | 91 |
| Alendronate Sodium | Alendronate Sodium | 401 | 104 |
| Jardiance | Empagliflozin | 398 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 96 |
| Furosemide | Furosemide | 377 | 114 |
| Simvastatin | Simvastatin | 377 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 372 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 369 | 100 |
| Carvedilol | Carvedilol | 331 | 102 |
| Alprazolam | Alprazolam | 302 | 70 |
| Omeprazole | Omeprazole | 268 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 267 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 264 | 75 |
| Spironolactone | Spironolactone | 250 | 55 |
| Ezetimibe | Ezetimibe | 246 | 63 |
| Testosterone Cypionate | Testosterone Cypionate | 240 | 62 |
| Meloxicam | Meloxicam | 236 | 56 |
| Trazodone Hcl | Trazodone Hcl | 196 | 48 |
| Lorazepam | Lorazepam | 193 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 192 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 185 | 45 |
| Trulicity | Dulaglutide | 182 | 34 |
| Montelukast Sodium | Montelukast Sodium | 179 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 176 | 46 |
| Potassium Chloride | Potassium Chloride | 175 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 37 |
| Eliquis | Apixaban | 160 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 157 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 153 | 31 |
| Nateglinide | Nateglinide | 150 | 51 |
| Tramadol Hcl | Tramadol Hcl | 148 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 135 | 26 |
| Farxiga | Dapagliflozin Propanediol | 132 | 32 |
| Pregabalin | Pregabalin | 132 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 32 |
| Warfarin Sodium | Warfarin Sodium | 125 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 27 |
| Novolog Flexpen | Insulin Aspart | 119 | 31 |
| Clonazepam | Clonazepam | 117 | 23 |
| Tradjenta | Linagliptin | 104 | 14 |
| Sertraline Hcl | Sertraline Hcl | 103 | 30 |
| Glimepiride | Glimepiride | 102 | 25 |
| Ramipril | Ramipril | 100 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 29 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 99 | 28 |
| Mounjaro | Tirzepatide | 98 | 21 |
| Estradiol | Estradiol | 94 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 36 |
| Januvia | Sitagliptin Phosphate | 91 | 15 |
| Sucralfate | Sucralfate | 89 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 81 | 20 |
| Diazepam | Diazepam | 80 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 18 |
| Metformin Hcl Er | Metformin Hcl | 76 | 18 |
| Lovastatin | Lovastatin | 75 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 14 |
| Famotidine | Famotidine | 72 | 25 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 71 | 58 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 71 | 24 |
| Prednisone | Prednisone | 68 | 13 |
| Sulindac | Sulindac | 68 | 17 |
| Bupropion Xl | Bupropion Hcl | 66 | 16 |
| Buspirone Hcl | Buspirone Hcl | 66 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 22 |
| Donepezil Hcl | Donepezil Hcl | 63 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 26 |
| Metoclopramide Hcl | Metoclopramide Hcl | 62 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 59 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 46 |
| Methimazole | Methimazole | 58 | 11 |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Valsartan | Valsartan | 57 | 14 |
| Azithromycin | Azithromycin | 56 | 45 |
| Fluconazole | Fluconazole | 56 | 34 |
| Propranolol Hcl | Propranolol Hcl | 55 | 11 |
| Testosterone | Testosterone | 54 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | suppressed |
| Fenofibrate | Fenofibrate | 48 | suppressed |
| Finasteride | Finasteride | 48 | 11 |
| Repatha Sureclick | Evolocumab | 46 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 33 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 11 |
| Primidone | Primidone | 43 | suppressed |
| Vascepa | Icosapent Ethyl | 43 | 11 |
| Risperidone | Risperidone | 42 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 36 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 40 | 11 |
| Klor-Con M20 | Potassium Chloride | 40 | 16 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | 12 |
| Insulin Lispro | Insulin Lispro | 38 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Humalog | Insulin Lispro | 37 | 11 |
| Ondansetron Odt | Ondansetron | 37 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 36 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Linzess | Linaclotide | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 30 |
| Prolia | Denosumab | 35 | 22 |
| Trimethoprim | Trimethoprim | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 32 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 31 | suppressed |
| Calcitriol | Calcitriol | 30 | suppressed |
| Repatha Syringe | Evolocumab | 30 | suppressed |
| Victoza 3-Pak | Liraglutide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 13 |
| Celecoxib | Celecoxib | 27 | 11 |
| Febuxostat | Febuxostat | 27 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 26 | suppressed |
| Nystatin | Nystatin | 26 | 14 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 24 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Cabergoline | Cabergoline | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Nadolol | Nadolol | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | 11 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Probenecid | Probenecid | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Symlinpen 120 | Pramlintide Acetate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Toviaz | Fesoterodine Fumarate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Insulin Syringe U-500 | Syringe,insul U-500,ndl,0.5ml | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xyosted | Testosterone Enanthate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,371.97 · 79 records | Amgen Inc. | ACCRUFER, AFREZZA, EVENITY, FANAPT, Fibroscan, GEMTESA, HETLIOZ, JARDIANCE, Kerendia, Korlym, LEQVIO, MINIMED 780G, OTEZLA, Omnipod, Ozempic, PROLIA, REPATHA, REZDIFFRA, Rybelsus, TEPEZZA, TWIIST, VOQUEZNA, Wegovy, XIFAXAN, XYOSTED, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error